Information
References
Contents
Academic Editor
- Agustín Ibáñez
Download
[1]Jack CR, Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association. 2024; 20: 5143–5169. https://doi.org/10.1002/alz.13859.
[2]Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. JAMA Neurology. 2024; 81: 1304–1311. https://doi.org/10.1001/jamaneurol.2024.3770.
[3]Petersen RC, Mormino E, Schneider JA. Alzheimer Disease-What’s in a Name? JAMA Neurology. 2024; 81: 1245–1246. https://doi.org/10.1001/jamaneurol.2024.3766.
[4]Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. 2024; 332: 1245–1257. https://doi.org/10.1001/jama.2024.13855.
[5]Frederiksen KS, Nielsen TR, Winblad B, Schmidt R, Kramberger MG, Jones RW, et al. European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. European Journal of Neurology. 2021; 28: 2147–2155. https://doi.org/10.1111/ene.14668.
[6]Kunneman M, Smets EMA, Bouwman FH, Schoonenboom NSM, Zwan MD, Pel-Littel R, et al. Clinicians’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimer’s & Dementia (New York, N. Y.). 2017; 3: 305–313. https://doi.org/10.1016/j.trci.2017.03.009.
[7]Grill JD, Apostolova LG, Bullain S, Burns JM, Cox CG, Dick M, et al. Communicating mild cognitive impairment diagnoses with and without amyloid imaging. Alzheimer’s Research & Therapy. 2017; 9: 35. https://doi.org/10.1186/s13195-017-0261-y.
[8]Linden I, Wolfs C, Perry M, Metsemakers J, van der Weijden T, de Vugt M, et al. Implementation of a diagnostic decision aid for people with memory complaints and their general practitioners: a protocol of a before and after pilot trial. BMJ Open. 2021; 11: e049322. https://doi.org/10.1136/bmjopen-2021-049322.
[9]Visser LNC, van Maurik IS, Bouwman FH, Staekenborg S, Vreeswijk R, Hempenius L, et al. Clinicians’ communication with patients receiving a MCI diagnosis: The ABIDE project. PloS One. 2020; 15: e0227282. https://doi.org/10.1371/journal.pone.0227282.
[10]Pérez de Lucas N, García-Llana H, Gómez-Iglesias E, Júdez Gutiérrez J. Planificación Compartida de la atención, comunicación y eutanasia. AMF. 2022; 18: 297–302. (In Spanish)
Academic Editor
- Agustín Ibáñez
Article Metrics
Download
- Contents
Information
Download
Contents
Alzheimer’s and Its Diagnosis: Are We Prepared to Accompany Our Patients? Shared Care Planning as a Relational Framework
, Pilar Alcántara-Miranda 1,2,3, Sonia Martínez-Morante 2,41 Servicio de Neurología, Hospital Universitario de Torrejón (HUT), 28850 Madrid, Spain
2 Miembro del Grupo de Planificación Compartida de la Atención del H.U.Torrejón, Madrid, Spain
3 Instituto de Neurociencias, Hospitales Vithas, Madrid, Spain
4 Instituto de Neurociencias Madrid, Hospitales Vithas, Madrid, Spain
References
- [1]
Jack CR, Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association. 2024; 20: 5143–5169. https://doi.org/10.1002/alz.13859. Cited within: 1Google Scholar - [2]
Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. JAMA Neurology. 2024; 81: 1304–1311. https://doi.org/10.1001/jamaneurol.2024.3770. - [3]
Petersen RC, Mormino E, Schneider JA. Alzheimer Disease-What’s in a Name? JAMA Neurology. 2024; 81: 1245–1246. https://doi.org/10.1001/jamaneurol.2024.3766. - [4]
Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. 2024; 332: 1245–1257. https://doi.org/10.1001/jama.2024.13855. - [5]
Frederiksen KS, Nielsen TR, Winblad B, Schmidt R, Kramberger MG, Jones RW, et al. European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. European Journal of Neurology. 2021; 28: 2147–2155. https://doi.org/10.1111/ene.14668. - [6]
Kunneman M, Smets EMA, Bouwman FH, Schoonenboom NSM, Zwan MD, Pel-Littel R, et al. Clinicians’ views on conversations and shared decision making in diagnostic testing for Alzheimer’s disease: The ABIDE project. Alzheimer’s & Dementia (New York, N. Y.). 2017; 3: 305–313. https://doi.org/10.1016/j.trci.2017.03.009. Cited within: 1Google Scholar - [7]
Grill JD, Apostolova LG, Bullain S, Burns JM, Cox CG, Dick M, et al. Communicating mild cognitive impairment diagnoses with and without amyloid imaging. Alzheimer’s Research & Therapy. 2017; 9: 35. https://doi.org/10.1186/s13195-017-0261-y. Cited within: 1Google Scholar - [8]
Linden I, Wolfs C, Perry M, Metsemakers J, van der Weijden T, de Vugt M, et al. Implementation of a diagnostic decision aid for people with memory complaints and their general practitioners: a protocol of a before and after pilot trial. BMJ Open. 2021; 11: e049322. https://doi.org/10.1136/bmjopen-2021-049322. - [9]
Visser LNC, van Maurik IS, Bouwman FH, Staekenborg S, Vreeswijk R, Hempenius L, et al. Clinicians’ communication with patients receiving a MCI diagnosis: The ABIDE project. PloS One. 2020; 15: e0227282. https://doi.org/10.1371/journal.pone.0227282. - [10]
Pérez de Lucas N, García-Llana H, Gómez-Iglesias E, Júdez Gutiérrez J. Planificación Compartida de la atención, comunicación y eutanasia. AMF. 2022; 18: 297–302. (In Spanish)
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.